Tag

rare and orphan drugs Archives - Optime Care

Optime Care
5
Rare Voices Podcast by Optime Care
News
February 8, 2021

“Rare Voices” Podcast Series Continues: Optime Care Further Explores Unique Perspectives of Exceptional People Reshaping Patient Experiences With Rare & Orphan Diseases

EARTH CITY, Mo.--Optime Care, a nationally recognized pharmacy, specialty distributor and patient management organization maximizing…
Read More
Optime Care
3
News
January 13, 2021

Optime Care Featured in HIT Consultant Industry Publication: Critical Role of a Specialty Pharmacist in the Management of Orphan and Rare Diseases

Optime Care Pharmacist-in-charge, Dr. Brandon Salke, PHARM.D, byline article featured on January 8, 2020: Why…
Read More
Michelle Hefley
4
Articles
November 23, 2020

How to Build an Integrated Service Model for Rare and Orphan Drugs

Six Questions You Should Ask a Consultant Many drug manufacturers and healthcare consultants attempt to…
Read More
Donovan Quill
3
Products first means patients get left behind
Articles
August 20, 2020

Product First Means Patients Left Behind

A tale of too many patients. My family has a long history of alpha-1 antitrypsin…
Read More
Optime Care
2
Optime Care Press Release
News
August 3, 2020

Optime Care Speeds Patient Recruitment for Clinical Trials of Specialty Rx for Orphan & Rare Disorders, Enhances Compliance, Retention and Overall Patient Experience

EARTH CITY, Mo.— Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing…
Read More
Donovan Quill
3
scale vs. service
Articles
July 13, 2020

Scale vs. Service? Your rare drug demands both.

When developing a drug commercialization strategy, there’s a misconception that patient service and program scalability are mutually exclusive. The prevailing…
Read More
Michelle Hefley
4
hub and spoke model for rare and orphan drugs
Articles
June 18, 2020

Revealing 5 hidden truths about using a hub-and-spoke model for rare and orphan drugs

The hub-and-spoke approach has become a standard of drug commercialization. Having a network of patient…
Read More